These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 6722409)

  • 21. The relative toxicity of disease-modifying antirheumatic drugs.
    Fries JF; Williams CA; Ramey D; Bloch DA
    Arthritis Rheum; 1993 Mar; 36(3):297-306. PubMed ID: 8452574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Anti-inflammatory or antirheumatic agents? Pharmacological activity and therapeutic effectiveness of non-steroid anti-inflammatory drugs: comparative study. III].
    Mariani L; Baratelli M
    Clin Ter; 1980 Feb; 92(4):331-58. PubMed ID: 7004749
    [No Abstract]   [Full Text] [Related]  

  • 23. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts.
    Wolfe F; Hawley DJ; Cathey MA
    J Rheumatol; 1990 Aug; 17(8):994-1002. PubMed ID: 1976811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis.
    Wooley PH; Griffin J; Panayi GS; Batchelor JR; Welsh KI; Gibson TJ
    N Engl J Med; 1980 Aug; 303(6):300-2. PubMed ID: 6770269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pattern of response to systematised drug therapy in rheumatoid arthritis in Indians.
    Malaviya AN; Khan KM; Tiwari SC
    Indian J Med Res; 1983 May; 77():686-96. PubMed ID: 6413397
    [No Abstract]   [Full Text] [Related]  

  • 26. Goldsalts, levamisole and D-penicillamine as first choice slow-acting antirheumatic drugs in rheumatoid arthritis--a long-term follow-up study.
    Veys EM; Mielants H; Verbruggen G
    Clin Exp Rheumatol; 1987; 5(2):111-6. PubMed ID: 3608266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delayed hypersensitivity to tuberculin in rats: effects of antirheumatic drugs.
    Bramm E; Binderup L; Arrigoni-Martelli E
    Acta Pharmacol Toxicol (Copenh); 1979 Jan; 44(1):75-80. PubMed ID: 104548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monocyte superoxide anion production in rheumatoid arthritis: preliminary evidence for enhanced rates of superoxide anion production by monocytes from patients receiving penicillamine, sodium aurothiomalate and corticosteroids.
    Hurst NP; Bessac B; Nuki G
    Ann Rheum Dis; 1984 Feb; 43(1):28-33. PubMed ID: 6320750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating thiomalate after administration of disodium aurothiomalate: impurity or active metabolite?
    Rudge SR; Perrett D; Swannell AJ; Drury PL
    J Rheumatol; 1984 Apr; 11(2):150-2. PubMed ID: 6427462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pharmacology of antirheumatic drugs.
    Parnham MJ
    Agents Actions Suppl; 1984; 14():153-69. PubMed ID: 6382972
    [No Abstract]   [Full Text] [Related]  

  • 31. [Interaction problems in the therapy with steroid-free anti-rheumatics].
    Husmann F
    Fortschr Med; 1981 Aug; 99(31-32):1231-5. PubMed ID: 7274937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Auranofin: experience to date.
    Blodgett RC
    Am J Med; 1983 Dec; 75(6A):86-9. PubMed ID: 6419601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Defining the toxicity of disease modifying antirheumatic drugs in rheumatoid arthritis.
    Furst DE
    J Rheumatol; 1991 Feb; 18(2):159-60. PubMed ID: 2023208
    [No Abstract]   [Full Text] [Related]  

  • 34. Safety issues related to DMARD therapy.
    Fries JF
    J Rheumatol Suppl; 1990 Nov; 25():14-7. PubMed ID: 2273518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Problems in the clinical use of non-steroidal antirheumatic agents].
    Mathies H
    Reumatizam; 1985; 32(1-2):1-4. PubMed ID: 4023460
    [No Abstract]   [Full Text] [Related]  

  • 36. The effect of antirheumatic drugs on circulating immune complexes in rheumatoid arthritis.
    Forster PJ; McConkey B
    Q J Med; 1986 Jan; 58(225):29-42. PubMed ID: 2871585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Risk factors for the development of side effects during treatment of rheumatoid arthritis with second-line antirheumatic agents; a review of the literature].
    Wijnands MJ; van Riel PL; Gribnau FW; van de Putte LB
    Ned Tijdschr Geneeskd; 1990 Jul; 134(29):1387-91. PubMed ID: 2197565
    [No Abstract]   [Full Text] [Related]  

  • 38. Rheumatoid arthritis. Practical use of medications.
    Furst DE
    Postgrad Med; 1990 Feb; 87(3):79-92. PubMed ID: 2406713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of action of disease modifying antirheumatic drugs.
    Harth M
    J Rheumatol Suppl; 1992 Jan; 32():100-3. PubMed ID: 1613728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A retrospective analysis of drug therapy in patients with rheumatoid arthritis.
    Bosmanský K; Trnavský K
    Z Rheumatol; 1983; 42(2):86-9. PubMed ID: 6880407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.